Form 4: Ligand Pharmaceuticals Executive Matthew Korenberg Acquires Shares Through Employee Stock Purchase Plan

Matthew Korenberg, President & Chief Operating Officer of Ligand Pharmaceuticals, acquired 350 shares of common stock through the company's Employee Stock Purchase Plan on June 28, 2024.

Summary

• On June 28, 2024, Matthew E. Korenberg, President & Chief Operating Officer of Ligand Pharmaceuticals, acquired 350 shares of common stock.
• The shares were purchased at a price of $60.707 per share.
• The acquisition was made through the Ligand Employee Stock Purchase Plan.
• Following the transaction, Korenberg directly owns 86,613 shares of Ligand Pharmaceuticals.
• The transaction was reported on July 2, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. Executive participation in the employee stock purchase plan is generally viewed as a positive sign, but the transaction itself is not significant enough to drastically alter sentiment.

Positives

• Executive participation in the Employee Stock Purchase Plan can signal confidence in the company's future.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it involves a small number of shares acquired through an existing employee program.

Key Dates